Cantor Fitzgerald Forecasts Strong Price Appreciation for Cypherpunk Technologies (NASDAQ:CYPH) Stock

Cypherpunk Technologies (NASDAQ:CYPH – Get Free Report) had its target price hoisted by analysts at Cantor Fitzgerald from $4.90 to $5.00 in a report released on Tuesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Cantor Fitzgerald‘s price target indicates a potential upside of 185.71% from the company’s previous close.

A number of other research analysts have also recently commented on CYPH. Wall Street Zen cut Cypherpunk Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Cypherpunk Technologies in a report on Friday, November 13th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $5.00.

Get Our Latest Stock Analysis on Cypherpunk Technologies

Cypherpunk Technologies Trading Down 8.1%

Cypherpunk Technologies stock opened at $1.75 on Tuesday. Cypherpunk Technologies has a 12 month low of $0.49 and a 12 month high of $4.19. The business’s 50 day simple moving average is $2.83 and its 200 day simple moving average is $1.37.

Cypherpunk Technologies (NASDAQ:CYPH – Get Free Report) last announced its quarterly earnings data on Monday, November 16th. The company reported $1.13 earnings per share for the quarter. The firm had revenue of $9.91 million for the quarter.

Insiders Place Their Bets

In other news, Director Patricia A. Martin sold 50,000 shares of the firm’s stock in a transaction on Wednesday, September 23rd. The stock was sold at an average price of $3.86, for a total value of $193,000.00. Following the completion of the transaction, the director directly owned 118,750 shares of the company’s stock, valued at $458,375. This trade represents a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Thomas Dietz sold 20,000 shares of the firm’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $1.72, for a total value of $34,400.00. Following the completion of the transaction, the director directly owned 132,500 shares of the company’s stock, valued at $227,900. The trade was a 13.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 3.50% of the company’s stock.

Institutional Trading of Cypherpunk Technologies

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC purchased a new stake in Cypherpunk Technologies during the 1st quarter worth about $576,000. SLT Holdings LLC purchased a new position in Cypherpunk Technologies during the 3rd quarter valued at about $1,152,000. Goldman Sachs Group Inc. bought a new stake in shares of Cypherpunk Technologies during the third quarter valued at about $957,000. Cygnus Capital Advisors LLC increased its position in shares of Cypherpunk Technologies by 2,044.6% during the second quarter. Cygnus Capital Advisors LLC now owns 246,460 shares of the company’s stock valued at $151,000 after buying an additional 234,968 shares during the period. Finally, Galaxy Digital Inc. bought a new stake in shares of Cypherpunk Technologies during the third quarter valued at about $666,000. 30.46% of the stock is currently owned by institutional investors.

About Cypherpunk Technologies

(Get Free Report)

Cypherpunk Technologies, Inc. is a digital-asset treasury company focused on Zcash, a cryptocurrency designed to support privacy-preserving transactions. Its strategy centers on acquiring and holding Zcash and supporting the broader ecosystem of privacy-focused technologies. The company was previously known as Leap Therapeutics, Inc., a clinical-stage biotechnology company that developed investigational cancer therapies. It later shifted away from its former focus on drug development and adopted the Cypherpunk Technologies name.

Further Reading

Receive News & Ratings for Cypherpunk Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cypherpunk Technologies and related companies with MarketBeat.com's FREE daily email newsletter.